The effect of foot positioning on tissue oxygenation in diabetic foot ulcers.

Diabetes Res Clin PractJul 21, 2026 (epub)
Clinical ResearchInternal Medicine (General)EndocrinologyGeriatrics

Fatemeh Khani, Gholamhossein Kazemzadeh, Mahdieh Arian

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial assessed the impact of foot positioning on tissue oxygenation in 60 hospitalized patients with diabetic foot ulcers. The study found that elevating the foot at 15° for 24 hours significantly improved transcutaneous oxygen pressure (5.26 ± 6.02 mmHg) compared to a decrease in the control group (-5.6 ± 7.3 mmHg, p = 0.027).

Key findings

  • Transcutaneous oxygen pressure increased by 5.26 ± 6.02 mmHg in the intervention group.
  • Ankle-brachial index improved by 0.14 ± 0.22 in the intervention group.
  • Toe-brachial index increased by 0.17 ± 0.21 in the intervention group.
  • Toe pressure rose by 18.5 ± 23.4 mmHg in the intervention group.

Why it matters

Improving tissue oxygenation is crucial for the management of diabetic foot ulcers, as it can enhance healing and reduce complications. Simple interventions like foot elevation can be easily integrated into patient care.

Source

PubMed · PMID 42480715

Published in Diabetes Res Clin Pract. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Internal Medicine (General)

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.